FDA approves Roche immunotherapy cocktail in liver cancer
Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2020 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
The U.S. Food and Drug Administration reviewed the Company's request for Fast Track designation and concluded that investigation of onvansertib, in combination with FOLFIRI/bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic col... Biopharmaceuticals, Oncology, FDA Cardiff Oncology, Onvansertib, Colorectal Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2020 Category: Pharmaceuticals Source Type: news
' Momentous' Data for First-Line Combo in Liver Cancer'Momentous' Data for First-Line Combo in Liver Cancer
The combination of atezolizumab and bevacizumab for the first-line treatment of unresectable hepatocellular carcinoma is set to become the new standard of care for this poor-prognosis cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New treatment extends lives of people with most common type of liver cancer
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.Researchers found that a combination of atezolizumab, an immunotherapy drug that boosts the body ’s natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors’ blood vessels, improved overall survival and reduced the risk of death by 42%. It also decreased the risk of the disease worsening by 41%, and the percentage of patients whose cancer shrank or disappeared more than doubled.R...
Source: UCLA Newsroom: Health Sciences - May 13, 2020 Category: Universities & Medical Training Source Type: news
Atezolizumab-Bevacizumab Beats Sorafenib in Liver Cancer
WEDNESDAY, May 13, 2020 -- Atezolizumab plus bevacizumab improves survival outcomes versus sorafenib in patients with unresectable hepatocellular carcinoma, according to a study published in the May 14 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2020 Category: Pharmaceuticals Source Type: news
FDA Approves Olaparib/Bevacizumab Maintenance FDA Approves Olaparib/Bevacizumab Maintenance
The FDA has announced a new approved indication for olaparib in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--May 8, 2020 -- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 8, 2020 Category: Drugs & Pharmacology Source Type: news
Low Doses of Bevacizumab Tested for Retinopathy of Prematurity
FRIDAY, April 24, 2020 -- For treatment of retinopathy of prematurity (ROP), 0.004 mg may be the lowest effective dose of bevacizumab, according to a study published online April 23 in JAMA Ophthalmology.
David K. Wallace, M.D., from the Jaeb Center... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2020 Category: Pharmaceuticals Source Type: news
Very low-dose Avastin effective for preventing blindness in preterm infants
NIH-funded study finds very low doses effective for treating retinopathy of prematurity. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 23, 2020 Category: American Health Source Type: news
Bevacizumab plus paclitaxel not cost effective for HER2 − MBC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2020 Category: Drugs & Pharmacology Source Type: news
Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements
Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone. (Source: CancerNetwork)
Source: CancerNetwork - March 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
